RxDoctor Payments Data

Sheldon Pike, MD

Urology · Lawrence, NYNPI 1225050412

Payments from drug & device makers

$5,938in general payments, 2019–2025

Across 198 payments — averaging $29.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • Johnson & Johnson$889
  • Neotract Inc.$640
  • Axonics, Inc.$499
  • Pfizer$339
  • Astellas Pharma US Inc$339
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,64195%
  • Education$2975%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,938 in reported general payments places this provider in the 65th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$367,394
Medicare patients
302
Services billed
2,734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate43$245,054
ElmironPentosan Polysulfate Sodium62$62,719
GemtesaVibegron78$44,378
MyrbetriqMirabegron74$37,270
PremarinEstrogens, Conjugated17$8,308
Testosterone12$3,438
Estradiol32$2,643
Solifenacin Succinate62$2,176
Fesoterodine Fumarate ErFesoterodine Fumarate29$1,825
Trospium Chloride36$1,764
Tamsulosin Hcl189$1,539
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst56$744
Dutasteride41$515
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip18$443
Bicalutamide27$351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLupron Depot$71$245,05443 claims
Sumitomo Pharma America, Inc.Gemtesa$175$44,37878 claims
Astellas Pharma US IncMyrbetriq$339$37,27074 claims
PfizerPremarin$339$8,30817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 952 urology providers in New York.

Other urology in Lawrence

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →